AbbVie Buys Cerevel Therapeutics for $8.7B, Bolstering Neuroscience Portfolio
AbbVie plans to buy Cerevel Therapeutics for $45 per share in a $8.7 billion deal to diversify its portfolio and strengthen its neuroscience drug pipeline.
( 1
min )